Paris (ots/PRNewswire) - * A new ambition by 2030 to accelerate its
* A visual identity, a marker of the successful transformation of
the Group, its ambitions and its renewal
Servier today unveils its 2030 ambition as well as a new visual
identity that reflects the transformation undertaken by the Group,
bringing visible results. The Group intends to accelerate its
transformation dynamics in order to ensure, over the long term, its
independence and its creation of value for all its stakeholders.
Servier confirms its commitment to making a meaningful social impact
and contributing to a sustainable world.
A transformation that leads to results
Servier committed in 2015 to a transformation aimed at sustainably
improving the company's performance and ensuring the sustainability
of its unique governance model for the ultimate benefit of patients.
Being governed by a foundation also gives the Group a long-term
vision, perfectly adapted to the long cycles of the pharmaceutical
In recent years, Servier has strengthened its leadership in
cardiovascular diseases, the leading cause of mortality worldwide
– Servier is the 3rd largest global pharmaceutical group in
cardiology and in hypertension. Drawing on recognized scientific
know-how, the Group has developed a wide range of treatments
distributed in 150 countries. Servier has significantly invested in
incremental innovation, including Single Pill Combinations (SPCs),
several medicines combined into a single tablet, which leads to
better patient compliance and contributes to savings for the
healthcare system. Servier is also a renowned global leader in venous
diseases, thanks to daflon® which is an important part of the Group's
Servier has made a major shift in oncology as a new pillar of
strategic growth. The Group allocates over 50% of its R&D budget to
it, with the ambition to become a renowned and innovative player in
the development of therapeutic solutions targeting hard-to-treat
cancers. Servier leads its R&D programs around two approaches:
immuno-oncology and targeted therapies. Over the past four years, the
Group has significantly strengthened its position in oncology thanks
to more than €6 billion investments, including two major acquisitions
which have made it possible to establish a presence in new strategic
territories such as the United States and Japan. The Group's major
investment in oncology today results in a rich pipeline of 39 R&D
projects and seven medicines available to patients.
The Group also consolidated its generic business through national
champions with strong brands such as Biogaran in France, Egis in
Eastern Europe, Pharlab in Brazil and Swipha in Nigeria. This
activity opens access to quality care for the largest number of
people and contributes to lowering healthcare costs.
The transformation has impacted all the Group's activities, including
R&D, which has undertaken a transformation plan based on three
pillars that support progress and therapeutic performance: a
patient-centric approach, a more efficient organization with a
collaborative dynamic, and a refocusing on four therapeutic areas
(oncology, cardiometabolism, neuroscience and immuno-inflammation).
In its ambition to build a very open, dynamic and productive research
for the benefit of patients, the opening of the Servier Research and
Development Institute at Paris-Saclay in 2023 is a major step in the
transformation of R&D. The result of an investment of more than €370
million, it is situated at the center of a global scientific and
technological innovation cluster. The future Institute will be the
heart of the Group's global R&D organization and will work
cross-functionally with Servier's other R&D centers based in Denmark
(Ballerup), the United States (Boston) and Hungary (Budapest). It
will accommodate 1,500 employees and will include an incubator
housing approximately 15 start-ups.
The Group has also accelerated its digital transformation to create
value for patients and healthcare stakeholders, while unlocking the
potential of teams, through new agile and efficient ways of working
as well as a transformed infrastructure.
Relying on a solid foundation, the Group is now able to confirm its
trajectory to 2025 – a revenue of
€6 billion, including €1 billion in oncology, and a Group EBITDA of
€1.3 billion – and to ambitiously address the second strategic step
of its transformation plan by 2030.
Olivier Laureau, President of Servier, says: "I want to thank all the
employees of the Group who contribute to the success of the company's
profound transformation, recognized worldwide by healthcare
professionals, patient associations and our partners. The path we
have travelled has allowed us to value our uniqueness: Servier is a
group governed by a foundation whose ultimate beneficiary is and will
always be the patient. This independence allows us to invest in the
long-term for the development of innovative therapeutic solutions to
meet high unmet medical needs."
A 2030 vision and ambition to accelerate the Group's transformation
Building on the 2025 goals as an important milestone, Servier has set
a 2030 ambition to accelerate its transformation. The Group thus
intends to achieve a turnover of €8 billion in 2030 with an EBITDA of
more than 30% through a strategy based on three pillars:
1 – Be a mid-size, focused and innovative player in oncology as well
as in neuroscience and immuno-inflammation
Thanks to the major investments made in R&D, the Group has strong
innovation capabilities and a rich pipeline of projects targeting
pathologies with a high unmet medical need. Servier thus intends to
launch a new molecular entity, or a new indication, every year in
oncology and to achieve a major launch in the area of
neuroscience/immuno-inflammation by 2030. Servier sets a goal of
achieving an oncology revenue greater than or equal to €3 billion in
2 – Accelerate the Group's leadership in cardiometabolism and venous
Servier is very involved in the development of incremental
innovations (Single Pill Combinations) as well as innovative digital
services that aim to improve diagnosis, knowledge of chronic diseases
and therapeutic compliance. The Group develops partnerships with
patient associations to offer services that are best suited to the
needs of patients and their families. The Group intends to achieve a
revenue greater than or equal to €3 billion in 2030 in this area by
relying on a renowned expertise, a strong capacity for incremental
innovation and an extensive international presence.
3 – Continue the profitable growth of the Generic business
Relying on national champions, the Group wishes, through its Generic
business, to facilitate access to treatments for a largest number of
patients. This business will seize the market opportunities offered
by patent exclusivity losses and biosimilar development, with a
targeted revenue of €1.8 billion by 2030.
Three strategic levers will help achieve the Group ambition:
1 – An optimized industrial network
To support its growth and its development, Servier will rely on an
industrial model based on an efficient and sustainable network of
specialized production sites, suited to the evolution of its
medicines' portfolio. This model will also use digital technologies
(Artificial Intelligence and Big data) in order to provide visibility
into the industrial activity and to anticipate production management
from beginning to end (end-to-end supply chain).
2 – Agile and efficient organization
An agile and efficient organization, aligned with strategic
ambitions, is a key performance lever. That is why Servier will
strengthen cross-functional decision-making and collaboration in
order to allow everyone within the Group to save time and focus on
tasks with high added value. In addition, digital technologies will
benefit all activities of the Group, and will help increase its
effectiveness, performance and therapeutic innovation capability.
3 – A community of employees committed to future generations
Since its creation, Servier has placed employees at the center of its
actions, recognizing them as the Group's main strength. To make
Servier 2030 a success, for the benefit of patients, the Group
creates an environment encouraging talent engagement, retention and
Beyond the strong commitments already made to reduce its carbon
footprint, accelerate diversity and inclusion and support
communities, in particular through Mécénat Servier, the Group plans
to invest in a flagship CSR project every three years.
A new visual identity emblematic of the Group's transformation
The transformation undertaken, of which the results are visible to
all of the Group's stakeholders, led Servier to change its visual
identity by adopting a brand platform that reflects the Group's
This new identity reflects what animates and represents Servier's
uniqueness: an independent group, governed by a foundation, committed
to therapeutic progress to serve patient needs. It is the marker of
Servier's successful transformation, its ambitions and its renewal.
It also reflects the uniqueness of the Group that works for the
common good and fully integrates CSR into its strategy.
The "moved by you" signature and the star symbolize the Group's
proximity to its stakeholders (patients, partners and employees). The
smile, represented by the curve of the "R", provides hope for
patients. It symbolizes the passion, empathy, expertise and
innovation that characterize Servier.
This new brand platform unites all employees around a common
identity, a source of inspiration on a daily basis. It also
strengthens the Group's employer brand: its vocation, and its
independence guaranteed by its foundation status, respond to the
younger generations' search for meaning.
Olivier Laureau, President of Servier, adds: "Our Group is founded on
a vocation that inspires us and around strong values that drive us.
The initiated transformation and our ambition represent a new chapter
in our history. More than ever, with Servier 2030, we are focused on
innovation and positive social impact thanks to an improved
profitability and bold choices."
Press contact: email@example.com
Founded to serve health, Servier is a global group governed by a
Foundation that aspires to have a meaningful social impact, both for
patients and for a sustainable world. With its unique governance
model, it can fully serve its vocation with a long-term vision: being
committed to therapeutic progress to serve patient needs. The 21,800
employees of the Group are committed to this shared vocation, source
of inspiration every day.
As a world leader in cardiology, Servier's ambition is to become a
renowned, focused and innovative player in oncology by targeting
hard-to-treat cancers. That is why the Group allocates over 50% of
its R&D budget to developing targeted and innovative therapies in
Neuroscience and immuno-inflammatory diseases are the future growth
driver. In these areas, Servier is focused on a limited number of
diseases in which accurate patient profiling makes it possible to
offer a targeted therapeutic response through precision medicine.
To promote access to quality care for all at a lower cost, the Group
also offers a range of quality generic drugs covering most
pathologies, relying on strong brands in France, Eastern Europe,
Brazil and Nigeria.
In all these areas, the Group includes the patient voice at each
stage of the life cycle of a medicine.
Headquartered in France, Servier relies on a strong geographical
footprint in over 150 countries and achieved a revenue of €4.7
billion in 2021.
More information on the new Group website: servier.com
Follow us on social media: LinkedIn, Facebook, Twitter, Instagram
Logo - https://mma.prnewswire.com/media/1914957/Servier_Logo.jpg
PDF - https://mma.prnewswire.com/media/1914996/Servier_PDF.pdf
 Inserm, 2017
 Source IQVIA, Analytics Link / World 74 countries / Mat Q1 2022
View original content to download
Digital press kit: http://www.ots.at/pressemappe/PR57381/aom
Christian Drastil: Wiener Börse Plausch
SportWoche & Sportgeschichte Ö Podcast: Stefan Kraft am virtuellen KW 47 Cover, Katar-Blick, Premierensiege Maier & Eberharter
Aktien auf dem Radar:Strabag, S Immo, Marinomed Biotech, Flughafen Wien, Zumtobel, Frequentis, Lenzing, Bawag, BTV AG, Kapsch TrafficCom, Linz Textil Holding, Rath AG, SBO, Warimpex, Oberbank AG Stamm, Amag, Erste Group, Österreichische Post, Polytec Group, RBI, Uniqa, Wienerberger.
Vienna International Airport
Die Flughafen Wien AG positioniert sich durch die geografische Lage im Zentrum Europas als eine der wichtigsten Drehscheiben zu den florierenden Destinationen Mittel- und Osteuropas. Der Flughafen Wien war 2016 Ausgangs- oder Endpunkt für über 23 Millionen Passagiere.
>> Besuchen Sie 64 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER